Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $8.6 million.

  • Serina Therapeutics' Cash & Equivalents rose 16937.5% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 16937.5%. This contributed to the annual value of $3.7 million for FY2024, which is 5180.47% down from last year.
  • According to the latest figures from Q3 2025, Serina Therapeutics' Cash & Equivalents is $8.6 million, which was up 16937.5% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Cash & Equivalents ranged from a high of $8.7 million in Q1 2024 and a low of $300000.0 during Q1 2023
  • Over the past 5 years, Serina Therapeutics' median Cash & Equivalents value was $781000.0 (recorded in 2021), while the average stood at $2.9 million.
  • Per our database at Business Quant, Serina Therapeutics' Cash & Equivalents tumbled by 5726.5% in 2023 and then soared by 280200.0% in 2024.
  • Over the past 5 years, Serina Therapeutics' Cash & Equivalents (Quarter) stood at $600000.0 in 2021, then increased by 7.5% to $645000.0 in 2022, then soared by 1081.24% to $7.6 million in 2023, then crashed by 51.8% to $3.7 million in 2024, then soared by 134.75% to $8.6 million in 2025.
  • Its Cash & Equivalents was $8.6 million in Q3 2025, compared to $6.0 million in Q2 2025 and $4.3 million in Q1 2025.